As we reported earlier this week, GW pharmaceuticals announced positive results from a late stage study of Epidiolex, a cannabidiol-based drug that is being studied for treatment of Dravet Syndrome, a rare and debilitating form of epilepsy in children. Following the announcement, the company’s stock price skyrocketed.
We found two additional articles that we think are well-worth reading. One from the MMJ Observer which provides more insight into the results of the Epidiolex Dravet Syndrome study – http://www.mmjobserver.com/marijuana-derived-drug-on-the-blink-of-fda-approval-for-treating-epilepsy-seizures/8350/ – and another from Seeking Alpha which also covers testing of other applications for the drug, and developments at other medical marijuana companies – http://seekingalpha.com/article/3958921-soaring-stock-price-gw-pharma-confirm-best-medical-marijuana-play.
